Publication at First Faculty of Medicine |
2013
Abstract
The incidence of prostate cancer is increasing incl. cases of castration-resistant prostate cancer. The method of choice in castration-resistant prostate cancer is chemotherapy (docetaxel ,cabazitaxel).
After chemotherapy failure the administration of abiraterone acetate or enzalutamide is indicated. Skeletal events are managed by denosumab or zoledronic acid.